Will Januvia take out Byetta?

November 12, 2006

OnThePharm thinks so. The GLP-1 based therapies are an exciting new class of diabetes medications. So far, Byetta has worked well for my patients – the jury is still out with Januvia. Merck certainly hopes that Januvia will rescue them.



Related posts:

  1. Is Januvia next?
  2. Januvia and Stevens-Johnson
  3. Are Actos and Avandia to blame for rising diabetes costs?
  4. Medication refills
  5. Alli is here
  6. Prescription medication pay for performance, and the rationale behind it
  7. 2007 Diabetes Year in Review


KevinMD.com on Facebook


  Follow on Twitter   Subscribe



Comments on this entry are closed.

Previous post: Another PCP goes concierge

Next post: Deja vu in the ER

Site Meter